Introduction {#sec0005}
============

Invasive disease caused by *Neisseria meningitidis* is an important global health concern, being associated with significant rates of mortality and long-term sequelae ([@bib0145]). The burden of meningococcal disease in Southeast Asia is poorly described, with few data on prevailing serogroups and antimicrobial susceptibility patterns ([@bib0150]). The Mahidol-Oxford Tropical Health Network (MORU) includes diagnostic microbiology laboratories in Thailand, Laos and Cambodia, where *N. meningitidis* is an infrequently isolated pathogen. Detection of a chloramphenicol-resistant strain of *N. meningitidis* at our laboratory site in Laos in November 2017 prompted a review of published reports of chloramphenicol resistance in *N. meningitidis* and review of chloramphenicol susceptibility amongst meningococcal isolates in our laboratory network. Although no longer standard therapy for meningococcal meningitis, chloramphenicol is commonly used in beta-lactam intolerant patients and is recommended as an alternative agent in international guidelines for treatment of meningococcal meningitis ([@bib0140], [@bib0080]), and therefore resistance to this agent remains an issue of clinical importance.

Chloramphenicol resistance in *N. meningitidis* has rarely been reported, first being described in 1998 in 11 isolates from Vietnam and one isolate from France, due to the presence of a chloramphenicol transferase gene (*catP*) possibly derived from a *Clostridium perfringens* transposable element ([@bib0040]). Two further isolates with the same *catP* insertion were later described in Australia ([@bib0115]) amongst 1382 isolates. More recently, chloramphenicol resistance was reported in one of 2888 isolates in Brazil ([@bib0045]), and a further highly resistant isolate was found in Vietnam in 2014 ([@bib0130]). Despite historical use of single-dose oily chloramphenicol for epidemic management of meningococcal meningitis ([@bib0035]), we could find no reports of chloramphenicol resistance from Africa, although susceptibility information on African isolates is limited ([@bib0060]).

We identified chloramphenicol resistance in eight of 25 isolates of *N. meningitidis* in our network laboratories over an 11 year time period. Given the seemingly high frequency of chloramphenicol resistance amongst our *N. meningitidis* isolates, we aimed to characterise the genetic basis of this using whole genome sequencing. In addition, due to the scarcity of meningococcal data from Southeast Asia, we report serogroup data and phenotypic and genotypic susceptibilities to other routinely tested antimicrobial agents in 18 of these isolates that were available for sequencing.

Methods {#sec0010}
=======

Study sites {#sec0015}
-----------

Clinical isolates from three laboratories were included. The Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Laos provides diagnostic microbiology services to Mahosot Hospital as well as other hospitals in Vientiane and other provincial sites. The Microbiology Laboratory of the Shoklo Malaria Research Unit (SMRU), Mae Sot, Thailand supports healthcare provision to marginalised populations on the Thailand-Myanmar border. The Cambodia-Oxford Medical Research Unit (COMRU) provides diagnostic microbiology services to the Angkor Hospital for Children, a paediatric teaching hospital in Siem Reap, Cambodia. All laboratories routinely store clinically significant bacterial isolates at -80 °C.

Sample selection, organism identification and phenotypic antimicrobial susceptibility testing {#sec0020}
---------------------------------------------------------------------------------------------

Laboratory records were reviewed for all clinical isolates of *N. meningitidis* up until 31st March 2018, with data available from year 2000 in LOMWRU, 2007 in SMRU and from 2013 in COMRU. A total of thirty-four isolates were identified (9 from LOMWRU, 18 from SMRU, 7 from COMRU), of which 25 had susceptibility data for chloramphenicol and were stored and viable. *N. meningitidis* isolates were originally identified by API NH (bioMérieux, France) and had undergone antimicrobial susceptibility testing (AST) by disk diffusion for chloramphenicol, ciprofloxacin and ceftriaxone, and Etest (bioMérieux, France) for penicillin, according to Clinical and Laboratory Standards Institute (CLSI) standards and breakpoints. Before genotypic characterisation, isolates were subcultured on to chocolate agar from storage at −80 °C and underwent confirmation of identity by MALDI-TOF (Vitek MS, bioMérieux) and AST repeated by Etest (bioMérieux, France) according to manufacturer\'s instructions and CLSI 2018 standards ([@bib0155]). Two isolates failed to confirm as *N. meningitidis*, and five were removed as duplicate isolates from patients in whom N. meningitidis was isolated from multiple sites, leaving 18 isolates for analysis.

Patient-related metadata {#sec0025}
------------------------

Demographic data, clinical syndrome, antibiotic treatment and status on discharge were obtained from laboratory records and patient charts where available.

Genotypic characterization {#sec0030}
--------------------------

Sequencing was performed at the MORU laboratories in Bangkok, Thailand. Libraries were made from extracted DNA using the Illumina Nextera XT library preparation kit (Illumina, San Diego, CA, USA) and quantified on an Agilent BioAnalyser (Agilent Technologies, Santa Clara, CA, USA). The pooled libraries were sequenced on one run of an Illumina MiSeq sequencer using the v2 reagent kit to give 250 bp paired-end reads. The genome assembly of chloramphenicol-resistant strain DuyDNT from Vietnam was obtained from Genbank under accession RPSF00000000.

Spades v3.11.1 ([@bib0005]) was used to assemble genomes from whole-genome sequencing. Abricate v0.8.10 ([@bib0105]) was used to look for acquired resistance genes using the bundled ResFinder database (updated 2018-10-02) ([@bib0160]). BLAST was used to search for specific antibiotic resistance genes. Prokka 1.13.3 was used to annotate the assembled genomes.

In silico serogrouping of the isolates was performed by retrieving the sequences of the genes in the capsule synthesis region of the capsule that are unique to each serogroup (*csb*, *csc*, *csw* and *csy*) for the B, C, W and Y serogroups respectively, and determining their presence or absence using BLAST to search the genome assemblies.

Snippy v4.3.6 ([@bib0110]) was used to call SNPs against the MC58 reference genome from raw sequence data and from the assembled DuyDNT genome. Initial phylogenetic trees were generated from the core SNP fasta files using IQ-TREE ([@bib0085]) under the GTR + F + ASC + R3model which was the best fit using BIC implemented in ModelFinder ([@bib0070]). The initial tree was used as input to Gubbins v2.3.1 ([@bib0015]) to generate a phylogeny accounting for recombination.

Results {#sec0035}
=======

Phenotypic characteristics and patient-related data {#sec0040}
---------------------------------------------------

Eighteen isolates of *N. meningitidis* (11 from Thailand, 5 from Cambodia, 2 from Laos) from 18 patients were included in the analysis ([Table 1](#tbl0005){ref-type="table"}). Eight of 18 (44.4%) meningococcal isolates were resistant to chloramphenicol. Four of the resistant isolates were collected from Thailand, and two each from Cambodia and Laos. All isolates were susceptible to ceftriaxone, but 10/18 (55.5%) isolates had reduced susceptibility to penicillin, including one isolate which was resistant according to CLSI criteria ([Table 2](#tbl0010){ref-type="table"}). Phenotypic ciprofloxacin resistance was detected in two isolates.Table 1Clinical information on the samples.Table 1PatientSample IDUnitSpecimen dateSample typeAge (years)SexDiagnosisAntibiotic therapyStatus at discharge1NM01SMRU25/7/07CSF7MMeningitisUnknownUnknown2NM03SMRU25/11/09BC1FSepsisCeftriaxoneWell3NM04SMRU15/11/10BC\<1MMeningitisCeftriaxoneWell4NM06SMRU19/6/11BC0.2MMeningitisUnknownUnknown5NM07SMRU4/10/11BC0.5MMeningitisCeftriaxoneWell6NM09SMRU7/1/12BC0.2MMeningitisCeftriaxoneWell7NM11SMRU18/1/12BC3MMeningitisCeftriaxoneWell8NM12SMRU28/12/12BC0.3FSepsisCeftriaxoneWell9NM13SMRU13/5/13BC0.6MSepsisCeftriaxoneWell10NM14SMRU15/2/14BC0.3FSepsisCeftriaxoneWell11NM15SMRU19/12/14BC0.3MSepsisUnknownWell12NM16LOMWRU10/11/17CSF60FMeningitisCeftriaxoneWell13NM18COMRU13/10/13BC0.14FMeningitis/SepsisCeftriaxoneWell14NM19COMRU25/4/14BC1.84FSepsisCeftriaxoneWell15NM20COMRU31/3/15BC0.91FPneumonia/SepsisCeftriaxoneWell16NM21COMRU24/7/16BC0.07MMeningitis/SepsisUnknownWell17NM23COMRU22/8/17BC0.33FMeningitisCeftriaxoneWell18NM25LOMWRU21/3/18BC0.25MMeningitisCeftriaxoneWell[^3][^4]Table 2Antibiotic resistance and genetic data on the samples. Minimum inhibitory concentration for each antibiotic is shown in brackets.Table 2Sample IDPhenotypic antibiotic susceptibilityGenotypic antibiotic resistancePEN phenotype/genotype discordanceSerogroupMLSTClonal complexCHLCIPCROPENNM01R (128)S (0.004)S (\<0.016)I (0.125)CHL, PENB1487NM03S (1)S (0.004)S (\<0.016)I (0.25)PENB14488ST-41/44 complexNM04S (2)S (0.004)S (\<0.016)S (0.064)B14489NM06S (2)S (0.004)S (\<0.016)S (0.064)B32ST-32 complexNM07S (1)R (0.125)S (\<0.016)I (0.25)PEN, CIP, TETC3256NM09S (2)S (0.004)S (\<0.016)S (0.064)B5604NM11R 128)S (0.004)S (\<0.016)S (0.064)CHLB14496NM12R (128)S (0.004)S (\<0.016)R (0.5)CHL, PENB1576NM13R (128)S (0.004)S (\<0.016)S (0.064)CHLB1576NM14S (2)S (0.004)S (\<0.016)I (0.25)PENB1145ST-41/44 complexNM15S (1)S (0.008)S (\<0.016)I (0.25)PENB41ST-41/44 complexNM16R (32)S 0.032S (0.002)I (0.125)CHLYesB1576NM18R (32)R (0.25)S (0.016)I (0.125)CHL, CIP, PENB1576NM19S (1)S (0.008)S (0.016)S (0.032)C14503ST-4821 complexNM20R (32)S (0.016)S (0.016)S (0.064)CHL, PENYesB11005NM21S (2)S (0.016)S (0.016)S (0.016)B12811NM23S (2)S (0.016)S (0.016)I (0.125)PENB14507NM25R (32)S (0.004)S (0.002)I (0.25)CHL, PENB1576[^5][^6]

Despite COMRU being the only site with a purely paediatric population, 17/18 patients were children under 8 years old, with a median age of approximately 4 months (one patient \<1 year old with no recorded date of birth was attributed the age of 1 year for the purposes of the calculation). Most patients presented with meningitis and/or sepsis, all patients with known antibiotic treatment (14/18) were treated with ceftriaxone, and all of the 16 patients with known outcome were discharged alive following clinical improvement.

Genotypic characterization {#sec0045}
--------------------------

All 18 isolates underwent sequencing. 0.4--2.4 million sequence reads were obtained from each isolate, giving 42-233X coverage of the genome. The genomes were assembled in 133-248 contigs, with a total length of 2,124,885--2,217,307 bp and n50 between 40.4 and 82.5 kb.

We determined the serogroups of the isolates from the genome assemblies by looking for the presence of the unique capsule synthesis genes for the B, C, W and Y serogroups which commonly cause invasive disease ([@bib0055]). Two isolates showed the presence of the *csc* gene, indicating they are serogroup C, while the other 16 isolates, including all the resistant isolates, had the *csb* gene, indicating they are serogroup B. No matches for the serogroup W or Y genes could be found.

We determined the sequence types of the isolates in our sample set ([Table 1](#tbl0005){ref-type="table"}). Of the chloramphenicol resistant isolates, five were ST-1576, one was ST-11005, and two isolates had novel sequence types (assigned as ST-14487 and ST-14496). ST-1576 and ST-11005 differ only at the *gdh* locus, and the two novel sequence types also differ from ST-1576 at only one locus. None of the chloramphenicol susceptible isolates were from ST-1576 or ST-11005, but they were from multiple sequence types, including four isolates with novel sequence types (assigned as ST-14488, ST-14489, ST-14503, and ST-14507). Two isolates from Thailand were ST-41 and ST-1145, and one was from ST-32. These sequence types are part of the ST-41/44 and ST-32 hypervirulent clonal complexes commonly seen in invasive disease ([@bib0100]). The novel ST-14488 sequence type was also part of the ST-41/44 complex. The ST-14503 isolate belonged to the ST-4821 clonal complex previously associated with an outbreak in China ([@bib0095]). The other isolates could not be assigned to a clonal complex.

By searching for the presence of antimicrobial resistance genes in the isolates, we identified a 623 bp *catP* chloramphenicol transferase gene with the same flanking sequences in all eight chloramphenicol resistant isolates. It had previously been shown that a *catP* gene was present in the highly chloramphenicol-resistant DuyDNT isolated in Vietnam in 2014, and the same *catP* gene and flanking regions also present in this isolate. By alignment of the region surrounding the *catP* gene to the MC58 reference genome, it was determined that the chloramphenicol resistance gene was found inserted between genes NMB1351 and NMB1352. The *catP* gene was identical to the *catP* gene previously reported in France ([@bib0040]) and a comparison of the sequences surrounding the insertion show that it was inserted in the same position in the genome (Supplementary Figure 1). The insertion is 986 bp identical to the Tn4451 transposon from *C. perfringens*, but contains only the *catP* gene and no complete flanking genes.

Ten of our isolates had reduced susceptibility or resistance to penicillin, including two of the chloramphenicol-resistant isolates (NM18 and NM25). We extracted the *penA* gene sequence to look for the five amino acid changes known to confer reduced susceptibility to penicillin ([@bib0125]). Nine isolates had all five amino acid changes, while the other nine isolates had none of the five changes. Concordance between the phenotypic and genotypic susceptibility was not complete -- one isolate (NM16) with reduced susceptibility phenotypically did not display the amino acid changes, while one isolate (NM20) with the *penA* changes did not show phenotypic reduced susceptibility ([Table 2](#tbl0010){ref-type="table"}). The isolate determined to be resistant to penicillin had the same *penA* allele as an isolate with only reduced susceptibility. The bla~ROB-1~ gene is also known to confer penicillin resistance in *N. meningitidis* ([@bib0135]), but this gene was not present in any of our strains.

Isolate NM07 from Thailand was found to contain the tetracycline resistance gene *tetB*. NM07 and NM18, carry the *gyrA* Thr91 → Ile mutation known to cause ciprofloxacin resistance ([@bib0025], [@bib0120]) and are both phenotypically resistant to ciprofloxacin.

We generated a phylogeny of the 18 genomes from this study and the previously-reported DuyDNT chloramphenicol-resistant isolate ([Figure 1](#fig0005){ref-type="fig"}) after removing recombinant SNPs, as *N. meningitidis* is highly recombinogenic ([@bib0030]). This shows that the chloramphenicol-resistant isolates from all four countries are in a single clade, with the isolates from each country clustered together within this clade.Figure 1A phylogeny of the 19 *Neisseria meningitidis* strains showing country of origin and resistance genotypes. The phylogeny was generated by Gubbins using RAxML and the scale bar indicates the number of SNPs.Figure 1

Discussion {#sec0050}
==========

We describe phenotypic and genotypic characteristics of 18 isolates of *N. meningitidis* from three countries in Southeast Asia isolated over an 11 year period. Most strikingly, chloramphenicol resistance, although rarely reported in the literature, was detected in a higher proportion (44.4%) of isolates compared to studies from other regions reporting on susceptibilities of large numbers of isolates, suggesting this is proportionately more common in Southeast Asia. The identical *catP* insertion across the isolates in this study and the previously reported isolates from Vietnam and Australia suggests that chloramphenicol resistance in *N. meningitidis* was acquired once in the ST-1576 lineage, and that lineage has now spread across Southeast Asia.

A high proportion of our isolates (55.5%) displayed reduced susceptibility to penicillin, 9/10 of which had genetic markers known to confer reduced penicillin susceptibility. However, a penicillin-susceptible isolate also carried these genetic markers, although the MIC in this isolate was close to the intermediate breakpoint. There may also be further genetic determinants of resistance in these strains, as we have limited knowledge of *N. meningitidis* genomes in Southeast Asia.

We also identified isolates resistant to multiple antibiotics including an isolate resistant to chloramphenicol and ciprofloxacin with reduced susceptibility to penicillin, and the DuyDNT isolate is susceptible to ciprofloxacin but carries a tetracycline resistance gene. The first reported chloramphenicol resistant *N. meningitidis* isolates were susceptible to penicillin, tetracycline, and quinolones ([@bib0040]), suggesting that this lineage has acquired resistance to multiple antibiotics during its spread.

Our isolates were predominantly serogroup B, with only two patients with strains from serogroup C. This is consistent with previous reports of serogroup B isolates causing sporadic disease in Thailand ([@bib0090], [@bib0010]) while very little information is available about common serogroups in Laos and Cambodia.

Five of the isolates we identified come from hypervirulent clonal complexes commonly implicated in invasive disease, including the ST-32 and ST-41/44 clonal complexes involved in multiple epidemics ([@bib0050]), and the ST-4821 clonal complex first identified in China in 2003 ([@bib0095]). The remaining thirteen isolates could not be assigned to one of these lineages, and many of these isolates were from novel sequence types. This suggests predominantly sporadic infection arising from the nasopharyngeal flora rather than an ongoing serogroup B epidemic.

There are several limitations of this study. The study involved only three sites and a relatively small number of isolates, reflecting the relative rarity of invasive meningococcal disease in our populations, giving only a snapshot of the epidemiology across the region. Furthermore, only culture-positive isolates were included, which may have underestimated the true number of cases and selected for more resistant isolates given the seemingly high prevalence of pre-hospital antibiotic treatment regionally ([@bib0075]), although relatively few additional cases were identified by routine CSF PCR for *N. meningitidis* in our laboratories. Nevertheless, our results suggest that resistance to chloramphenicol is relatively common in meningococcal isolates from Southeast Asia. This remains clinically important given the role of chloramphenicol as a common second-line agent for treatment of meningococcal meningitis. *N. meningitidis* which is non-susceptible to third-generation cephalosporins ([@bib0020]) has been recently reported in France, with a *penA* allele which may have been acquired from *Neisseria gonorrhoeae*, raising the possibility that recombination with extensively drug-resistant *N. gonorrhoeae* could result in the spread of further drug resistance in *N. meningitidis*. Our phenotypic and genotypic characterisation of isolates from three countries in Southeast Asia will add to the limited published data of the epidemiology of meningococcal disease in Southeast Asia, and aid future surveillance of drug-resistant isolates.
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